Translating plasma eicosapentaenoic acid concentrations into erythrocyte percentages of eicosapentaenoic acid plus docosahexaenoic acid during treatment with icosapent ethyl
The Reduction of Cardiovascular Events with Icosapent Ethyl –Intervention Trial (REDUCE-IT) study demonstrated that 4 g/d of eicosapentaenoic acid (EPA) ethyl esters (icosapent ethyl [IPE]) reduced risk for major cardiovascular events by 25% in statin-treated patients with residual hypertriglyceridemia. How this treatment affected red blood cell (RBC) EPA and docosahexaenoic acid (DHA) levels (ie, the Omega-3 Index [O3I]) was not reported, but effects on plasma EPA concentrations were reported.
Source: Journal of Clinical Lipidology - Category: Lipidology Authors: William S. Harris, Kristina H. Jackson Tags: Original Article Source Type: research
More News: Cardiology | Cardiovascular | Cholesterol | Heart | Lipidology | Omega 3 | Statin Therapy | Study